Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Sterility & contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections.

6,317 FDA drug recalls with this cause, newest first.

This is the single biggest cause in the register by a wide margin. It covers products that had to be sterile - injectables, eye drops, certain ointments - but could not be verified sterile, or were found contaminated during testing. Most of these recalls come from compounding pharmacies and outsourcing facilities after an FDA inspection finds gaps in how sterile products were made. Sterility failures are treated seriously because the products involved have the least room for error, going straight into the bloodstream or the eye.

Class II · Moderate risk

Hcg - 10

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-0216-49 D-0274-2015
Class II · Moderate risk

Tri Mix PF SYR 0.5 mL Inj.

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-5036-49 D-0273-2015
Class II · Moderate risk

Hcg-20

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-2195-47 D-0272-2015
Class II · Moderate risk

Cyclosporine 0.045 % Sol PF

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-5120-67 D-0271-2015
Class II · Moderate risk

2Ml HCG 10

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-7945-17 D-0270-2015
Class II · Moderate risk

Hcg 10

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-5012-34 D-0269-2015
Class II · Moderate risk

HCG 200 IU/mL Injection

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-7745-68 D-0268-2015
Class II · Moderate risk

HCG Low Dose 10 IU / 0.1 mL

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-2596-17 D-0267-2015
Class II · Moderate risk

Tri-mix Antidote 10 each Syringes

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-0205-17 D-0266-2015
Class II · Moderate risk

HCG Low Dose 30 IU/0.1 mL

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-0231-54 D-0265-2015
Class II · Moderate risk

Testosterone Cyp 200 mg/mL Sesame Inj.

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-7906-71 D-0264-2015
Class II · Moderate risk

Phenylephrine HCl

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-5230-12 D-0263-2015
Class II · Moderate risk

Leuprolide 50 mcg/0.1 mL Micro Lupron Kit

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-1124-57 D-0262-2015
Class II · Moderate risk

Tri-Mix

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-5123-09 D-0261-2015
Class II · Moderate risk

Methyl B12 25 mg/mL Inj.

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-2014-37 D-0260-2015
Class II · Moderate risk

Testosterone CYP-250/PROP-20 mg

Lack of sterility assurance;All lots of sterile products compounded by the pharmacy that are within expiry were recalled due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Terminated Sterility / contamination Perry Drug Inc. NDC 88888-0326-44 D-0259-2015
Class II · Moderate risk

Tri-mix #4

Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy's ability to consistently assure sterility of their products.

Terminated Sterility / contamination Vann Healthcare Services Inc D-0312-2015
Class II · Moderate risk

Lidocaine 4% Syr

Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy's ability to consistently assure sterility of their products.

Terminated Sterility / contamination Vann Healthcare Services Inc D-0311-2015
Class II · Moderate risk

Epinephrine 1:1000

Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy's ability to consistently assure sterility of their products.

Terminated Sterility / contamination Vann Healthcare Services Inc D-0310-2015
Class II · Moderate risk

Hydroxyprogesterone Caproate

Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy's ability to consistently assure sterility of their products.

Terminated Sterility / contamination Vann Healthcare Services Inc D-0309-2015
Class II · Moderate risk

Sterile Water for Injection

Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7990-09 D-0287-2015
Class II · Moderate risk

0.45% Sodium Chloride Injection

Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7985-09 D-0286-2015
Class II · Moderate risk

0.9% Sodium Chloride Injection

Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7983-09 D-0285-2015
Class II · Moderate risk

Lactated Ringer's Injection

Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7953-09 D-0283-2015